| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Thomas R Einarson, Hanna Pudas, Roman Zilbershtein, Rasmus Jensen, Colin Vicente, Charles Piwko, Michiel E H Hemel. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. Journal of medical economics. vol 16. issue 9. 2014-04-07. PMID:23844621. |
this study determined the cost-effectiveness of long-acting antipsychotic (lai) drugs paliperidone palmitate (pp-lai), olanzapine pamoate (olz-lai), and risperidone (ris-lai) for chronic schizophrenia. |
2014-04-07 |
2023-08-12 |
Not clear |
| Hikaru Hori, Kenji Yamada, Dan Kamada, Yuka Shibata, Asuka Katsuki, Reiji Yoshimura, Jun Nakamur. Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. Neuropsychiatric disease and treatment. vol 10. 2014-04-07. PMID:24707178. |
effect of blonanserin on cognitive and social function in acute phase japanese schizophrenia compared with risperidone. |
2014-04-07 |
2023-08-13 |
Not clear |
| Hikaru Hori, Kenji Yamada, Dan Kamada, Yuka Shibata, Asuka Katsuki, Reiji Yoshimura, Jun Nakamur. Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. Neuropsychiatric disease and treatment. vol 10. 2014-04-07. PMID:24707178. |
this study aims to determine the effectiveness of blonanserin (bns) on the cognitive and social functions of patients with schizophrenia compared with risperidone (ris) during acute-phase (8-week) treatment. |
2014-04-07 |
2023-08-13 |
Not clear |
| Zhen-Hua Chen, Gao-Hua Wang, Xiao-Ping Wang, Ren-Yun Chen, Hui-Lin Wang, Ming-Hua Yang, Yun-Xiang Huo, Hong-Bing Me. Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial. Current therapeutic research, clinical and experimental. vol 69. issue 2. 2014-04-02. PMID:24692790. |
effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: an 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial. |
2014-04-02 |
2023-08-13 |
Not clear |
| Javier Sanz-Fuentenebro, Diana Taboada, Tomás Palomo, María Aragües, Santiago Ovejero, Cristina Del Alamo, Vicente Molin. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophrenia research. vol 149. issue 1-3. 2014-03-11. PMID:23870807. |
randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. |
2014-03-11 |
2023-08-12 |
Not clear |
| Javier Sanz-Fuentenebro, Diana Taboada, Tomás Palomo, María Aragües, Santiago Ovejero, Cristina Del Alamo, Vicente Molin. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophrenia research. vol 149. issue 1-3. 2014-03-11. PMID:23870807. |
our research group is developing a non-commercial, multicentric and open label study on the differential efficacy between clozapine and risperidone in first-episode schizophrenia. |
2014-03-11 |
2023-08-12 |
Not clear |
| Susan D'Souza, Jabar A Faraj, Stefano Giovagnoli, Patrick P Deluc. Development of Risperidone PLGA Microspheres. Journal of drug delivery. vol 2014. 2014-03-11. PMID:24616812. |
the aim of this study was to design and evaluate biodegradable plga microspheres for sustained delivery of risperidone, with an eventual goal of avoiding combination therapy for the treatment of schizophrenia. |
2014-03-11 |
2023-08-12 |
rat |
| Richard Williams, Ranjith Chandrasena, Linda Beauclair, Doanh Luong, Annette La. Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada. Neuropsychiatric disease and treatment. vol 10. 2014-03-06. PMID:24600227. |
risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic schizophrenia treatment adherence registry in canada. |
2014-03-06 |
2023-08-12 |
Not clear |
| Richard Williams, Ranjith Chandrasena, Linda Beauclair, Doanh Luong, Annette La. Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada. Neuropsychiatric disease and treatment. vol 10. 2014-03-06. PMID:24600227. |
to assess outcomes over 24 months in canadian patients with schizophrenia initiated on risperidone long-acting injection (rlai) and participating in the electronic schizophrenia treatment adherence registry (e-star). |
2014-03-06 |
2023-08-12 |
Not clear |
| Maryam Noroozian, Sina Ghasemi, Seyed-Mohammad-Reza Hosseini, Amirhossein Modabbernia, Mohammad-Reza Khodaie-Ardakani, Omid Mirshafiee, Mehdi Farokhnia, Masih Tajdini, Farzin Rezaei, Bahman Salehi, Mandana Ashrafi, Habibeh Yekehtaz, Mina Tabrizi, Shahin Akhondzade. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology. vol 228. issue 4. 2014-03-05. PMID:23515583. |
a placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. |
2014-03-05 |
2023-08-12 |
Not clear |
| Krithika Rajagopalan, Mariam Hassan, Ken O'Day, Kellie Meyer, Fred Grossma. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of medical economics. vol 16. issue 7. 2014-03-03. PMID:23701260. |
compare long-term costs and outcomes of lurasidone to aripiprazole among adults with schizophrenia in the us who previously failed ≥1 atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone) based on an indirect comparison of outcomes data from clinical trials. |
2014-03-03 |
2023-08-12 |
Not clear |
| Sarah M Leatherman, Matthew H Liang, John H Krystal, Robert A Lew, Danielle Valley, Soe Soe Thwin, Robert A Rosenhec. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. The Journal of nervous and mental disease. vol 202. issue 1. 2014-02-21. PMID:24375206. |
differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. |
2014-02-21 |
2023-08-12 |
human |
| Sarah M Leatherman, Matthew H Liang, John H Krystal, Robert A Lew, Danielle Valley, Soe Soe Thwin, Robert A Rosenhec. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. The Journal of nervous and mental disease. vol 202. issue 1. 2014-02-21. PMID:24375206. |
a long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (lai) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes. |
2014-02-21 |
2023-08-12 |
human |
| Sarah M Leatherman, Matthew H Liang, John H Krystal, Robert A Lew, Danielle Valley, Soe Soe Thwin, Robert A Rosenhec. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. The Journal of nervous and mental disease. vol 202. issue 1. 2014-02-21. PMID:24375206. |
the initial analyses did not examine whether benefits of lai emerged in selected subgroups.patients with schizophrenia or schizoaffective disorder who had been hospitalized within the past 2 years or judged to be at risk for hospitalization because of increasing psychiatric service use were randomly assigned to lai risperidone 12.5 to 50 mg per injection biweekly or to the psychiatrist's choice of oral antipsychotics and followed for up to 2 years. |
2014-02-21 |
2023-08-12 |
human |
| Hidenobu Suzuki, Keishi Gen, Masahiro Otomo, Yuichi Inoue, Hiroyuki Hibino, Ayako Mikami, Hideo Matsumoto, Katsunaka Mikam. Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia. Psychiatry and clinical neurosciences. vol 67. issue 2. 2014-01-30. PMID:23438159. |
study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia. |
2014-01-30 |
2023-08-12 |
Not clear |
| Hidenobu Suzuki, Keishi Gen, Masahiro Otomo, Yuichi Inoue, Hiroyuki Hibino, Ayako Mikami, Hideo Matsumoto, Katsunaka Mikam. Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia. Psychiatry and clinical neurosciences. vol 67. issue 2. 2014-01-30. PMID:23438159. |
we investigated the clinical efficacy and safety of switching to paliperidone (pal) in elderly schizophrenia patients receiving risperidone. |
2014-01-30 |
2023-08-12 |
Not clear |
| Jeffrey A Lieberman, Geoffrey Dunbar, Anthony C Segreti, Ragy R Girgis, Frances Seoane, Jessica S Beaver, Naihua Duan, David A Hosfor. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 38. issue 6. 2014-01-21. PMID:23303043. |
in the united states and india, 185 outpatients (18-60 years; male 69%; 46% tobacco users) with schizophrenia treated with quetiapine or risperidone monotherapy were randomized to 12 weeks of placebo (n=91) or tc-5619 (n=94; orally once daily 1 mg day 1 to week 4, 5 mg week 4 to 8, and 25 mg week 8 to 12). |
2014-01-21 |
2023-08-12 |
human |
| Yun Liu, Meng-qi Zhang, Jing-ying Jia, Yan-mei Liu, Gang-yi Liu, Shui-jun Li, Wei Wang, Li-ping Weng, Chen Y. Bioequivalence and pharmacokinetic evaluation of two formulations of risperidone 2 mg : an open-label, single-dose, fasting, randomized-sequence, two-way crossover study in healthy male Chinese volunteers. Drugs in R&D. vol 13. issue 1. 2014-01-20. PMID:23322527. |
risperidone is a benzisoxazole derivate and is effective in the treatment of schizophrenia and other psychiatric illnesses in adults and children. |
2014-01-20 |
2023-08-12 |
human |
| Pablo Barrio, Albert Batalla, Pere Castellví, Diego Hidalgo, Marta García, Ana Ortiz, Iria Grande, Alexandre Pons, Eduard Parellad. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. International clinical psychopharmacology. vol 28. issue 4. 2014-01-17. PMID:23587986. |
effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. |
2014-01-17 |
2023-08-12 |
Not clear |
| Pablo Barrio, Albert Batalla, Pere Castellví, Diego Hidalgo, Marta García, Ana Ortiz, Iria Grande, Alexandre Pons, Eduard Parellad. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. International clinical psychopharmacology. vol 28. issue 4. 2014-01-17. PMID:23587986. |
the aim of the study was to compare the clinical remission rates, number of hospital readmissions and personal and social functioning after 2 years between patients with recent-onset schizophrenia (<2 years) in treatment with risperidone long-acting injectable (rlai) and patients with recent-onset schizophrenia receiving oral antipsychotics. |
2014-01-17 |
2023-08-12 |
Not clear |